免疫疗法
癌症研究
CCL5
趋化因子
肿瘤微环境
癌症免疫疗法
获得性免疫系统
免疫系统
CD8型
T细胞
生物
树突状细胞
免疫学
白细胞介素12
细胞毒性T细胞
白细胞介素2受体
体外
生物化学
作者
Nicole Kirchhammer,Marcel P. Trefny,Marina Natoli,Dominik Brücher,Sheena N. Smith,Franziska Werner,Victoria Koch,David Schreiner,Ewelina Magdalena Bartoszek,Mélanie Buchi,Markus Schmid,Daniel Breu,Karen Patricia Hartmann,Polina Zaytseva,Daniela S. Thommen,Heinz Philipp Laubli,Jan P. Böttcher,Michal A. Stanczak,Abhishek S. Kashyap,Andreas Plückthun
标识
DOI:10.1126/scitranslmed.abm9043
摘要
Abstract T cell-directed cancer immunotherapy often fails to generate lasting tumor control. Harnessing additional effectors of the immune response against tumors may strengthen the clinical benefit of immunotherapies. Here, we demonstrate that therapeutic targeting of the IFNγ-IL-12 pathway relies on the ability of a population of tissue-resident NK (trNK) cells to orchestrate an anti-tumor microenvironment. Particularly, utilizing an engineered adenoviral platform, we show that paracrine IL-12 enhances functional DC-CD8 T cell interactions to generate adaptive anti-tumor immunity. This effect depends on the abundance of trNK cells and specifically their capacity to produce the cDC1-chemoattractant CCL5. Failure to respond to IL-12 and other IFNγ-inducing therapies such as immune checkpoint blockade in tumors with low trNK cell infiltration could be overcome by intra-tumoral delivery of CCL5. Our findings reveal a novel barrier for T cell-focused therapies and offer mechanistic insights into how T cell-NK cell-DC crosstalk can be enhanced to promote anti-tumor immunity and overcome resistance. Significance We identified the lack of CCL5-producing, tissue-resident NK (trNK) cells as a barrier to T cell-focused therapies. While IL-12 induces anti-tumoral DC-T cell crosstalk in trNK cell rich tumors, resistance to IL-12 or anti-PD-1 in trNK cell poor tumors can be overcome by the additional delivery of CCL5.
科研通智能强力驱动
Strongly Powered by AbleSci AI